1Department of Radiation Oncology, Seoul National University Bundang Hospital, Seongnam, Korea
2Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea
3Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Korea
4Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea
5Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
6Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea
7Institute of Radiation Medicine, Medical Research Center, Seoul National University, Seoul, Korea
Copyright © 2022 by the Korean Cancer Association
This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Ethical Statement
Informed consent was waived and study protocol was approved by the institutional review board (IRB No. H-2105-142-1220).
Author Contributions
Conceived and designed the analysis: Jang BS, Kim TY, Chie EK.
Collected the data: Chang JH, Jeon SH, Song MG, Lee KH, Im SA, Kim JI, Kim TY, Chie EK.
Contributed data or analysis tools: Chang JH, Jeon SH, Song MG, Lee KH, Im SA, Kim JI, Kim TY, Chie EK.
Performed the analysis: Jang BS, Kim TY.
Wrote the paper: Jang BS.
Conflicts of Interest
Conflict of interest relevant to this article was not reported.
Variable | NDLC (n=41, 46.6%) | DLC (n=47, 53.4%) | p-value |
---|---|---|---|
Age at RT (yr) | 53 (18–76) | 54 (29–80) | 0.801 |
Sex | |||
Female | 25 (61.0) | 28 (59.6) | > 0.99 |
Male | 16 (39.0) | 19 (40.4) | |
Specimen type | |||
Metastatic | 21 (51.2) | 33 (70.2) | 0.082 |
Primary | 20 (48.8) | 14 (29.8) | |
RT site | |||
Abdomen | 3 (7.3) | 4 (8.5) | 0.588 |
Bone | 17 (41.5) | 22 (46.8) | |
Brain | 7 (17.1) | 4 (8.5) | |
Breast | 1 (2.4) | 0 | |
Chest wall | 1 (2.4) | 1 (2.1) | |
Cutaneous | 1 (2.4) | 0 | |
Head and neck | 3 (7.3) | 6 (12.8) | |
Lung | 0 ( | 2 (4.3) | |
Lymph node | 3 (7.3) | 1 (2.1) | |
Mediastinum | 1 (2.4) | 4 (8.5) | |
Pelvis | 3 (7.3) | 3 (6.4) | |
Soft tissue | 1 (2.4) | 0 | |
RT intent | |||
Definitive | 2 (4.9) | 7 (14.9) | 0.213 |
Palliative | 37 (90.2) | 35 (74.5) | |
Pre-op | 0 | 2 (4.3) | |
Salvage | 2 (4.9) | 3 (6.4) | |
RT modalities | |||
2-Dimensional radiotherapy | 6 (14.6) | 5 (10.6) | 0.529 |
3-Dimensional conformal radiotherapy | 8 (19.5) | 15 (31.9) | |
Brachytherapy | 0 | 1 (2.1) | |
Intensity modulated radiotherapy | 22 (53.7) | 23 (48.9) | |
Stereotactic body radiotherapy | 5 (12.2) | 3 (6.4) | |
ECOG performance status at RT (grade) | |||
0 | 2 (4.9) | 14 (29.8) | 0.003 |
1 | 25 (61.0) | 27 (57.4) | |
2 | 12 (29.3) | 4 (8.5) | |
3 | 2 (4.9) | 2 (4.3) | |
Completion of RT | |||
No | 5 (12.2) | 1 (2.1) | 0.093 |
Yes | 36 (87.8) | 46 (97.9) | |
Extracranial disease at RT | |||
Absence | 6 (14.6) | 15 (31.9) | 0.080 |
Presence | 35 (85.4) | 32 (68.1) | |
RT dose (Gy) | 30 (15–68) | 30 (14–68) | 0.604 |
RT fractions | 10 (1–30) | 10 (1–38) | 0.744 |
BED10 (Gy) | |||
≤ 50 | 7 (17.1) | 12 (25.5) | 0.438 |
> 50 | 34 (82.9) | 35 (74.5) |
Values are presented as median (range) or number (%). BED10, biologically effective dose with α/β=10; DLC, durable local control group; ECOG, Eastern Cooperative Oncology Group; NDLC, non-durable local control group; RT, radiation therapy. p-value was computed by chi-square test.
Values are presented as median (range) or number (%). BED10, biologically effective dose with α/β=10; DLC, durable local control group; ECOG, Eastern Cooperative Oncology Group; NDLC, non-durable local control group; RT, radiation therapy. p-value was computed by chi-square test.